Definium Therapeutics (DFTX) Operating Expenses (2021 - 2026)

Definium Therapeutics (DFTX) has reported Operating Expenses for 6 consecutive years, with $59.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 84.15% year-over-year to $59.2 million; the TTM figure through Mar 2026 stood at $193.4 million (up 69.81% YoY), while the FY2025 annual figure was $166.3 million, up 60.04% from the prior year.
• Operating Expenses advanced to $59.2 million in Q1 2026 per DFTX's latest filing, from $47.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $59.2 million in Q1 2026 and bottomed at $13.9 million in Q4 2022.
• Historically, Operating Expenses has averaged $28.8 million across 5 years, with a median of $24.5 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses slumped 62.53% — and 2025, when it soared 84.21%.
• Definium Therapeutics' Operating Expenses stood at $13.9 million in 2022, then soared by 59.75% to $22.2 million in 2023, then soared by 46.19% to $32.5 million in 2024, then surged by 46.57% to $47.6 million in 2025, then advanced by 24.47% to $59.2 million in 2026.
• Business Quant data shows DFTX's Operating Expenses at $59.2 million in Q1 2026, $47.6 million in Q4 2025, and $45.7 million in Q3 2025.